- Home
- ANTX
as 10-04-2024 4:00pm EST
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 63.5M | IPO Year: | 2022 |
| Target Price: | $2.50 | AVG Volume (30 days): | 204.5K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $22.22 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of AN2 Therapeutics Inc. (ANTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | ANTX | 10% Owner | Aug 14 '24 | Buy | $1.04 | 1,500,000 | $1,560,000.00 | 5,749,432 | |
| RA CAPITAL MANAGEMENT, L.P. | ANTX | 10% Owner | Aug 9 '24 | Sell | $1.08 | 3,525,094 | $3,807,101.52 | 1,725,348 |
Latest AN2 Therapeutics Inc. News
ANTX Breaking Stock News: Dive into ANTX Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Zacks
2 months ago
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
MT Newswires
2 months ago
AN2 Therapeutics Adopts Rights Plan After BML Investment Partners Nears 20% Stake
Business Wire
2 months ago
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
Business Wire
2 months ago
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
MT Newswires
2 months ago
Sector Update: Health Care
MT Newswires
2 months ago
Top Midday Decliners
Benzinga
2 months ago
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce
Compare ANTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANTX AN2 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.